| Gene symbol | GRB2 | Synonyms | ASH, EGFRBP-GRB2, Grb3-3, MST084, MSTP084, NCKAP2 | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q25.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | growth factor receptor bound protein 2 | ||||
| GTO ID | GTC2270 |
| Trial ID | NCT04196257 |
| Disease | Endometrial Cancer | Epithelial Ovarian Cancer | Fallopian Tube Neoplasm | Peritoneal Carcinoma |
| Altered gene | GRB2 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | BP1001|Liposomal Grb2 Antisense Oligonucleotide|Liposomal Grb-2|L-Grb-2 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors |
| Year | 2022 |
| Country | United States |
| Company sponsor | Bio-Path Holdings, Inc. |
| Other ID(s) | BP1001-A-101-GynOnc |
| Vector information | |||
|
|||
| Cohort1: BP1001-A | |||||||
|
|||||||
| Cohort2: BP1001-A_paclitaxel | |||||||
|
|||||||